The UCHL5 inhibitor b-AP15 overcomes cisplatin resistance via suppression of cancer stemness in urothelial carcinoma

Urothelial carcinoma (UC) comprises the majority of bladder cancers. Standard platinum-based chemotherapy has a response rate of approximately 50%, but drug resistance develops after short-term treatment. Deubiquitinating (DUB) enzyme inhibitors increase protein polyubiquitination and endoplasmic re...

Descripción completa

Detalles Bibliográficos
Autores principales: Chow, Po-Ming, Dong, Jun-Ren, Chang, Yu-Wei, Kuo, Kuan-Lin, Lin, Wei-Chou, Liu, Shing-Hwa, Huang, Kuo-How
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9421311/
https://www.ncbi.nlm.nih.gov/pubmed/36090476
http://dx.doi.org/10.1016/j.omto.2022.08.004

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9421311/
https://www.ncbi.nlm.nih.gov/pubmed/36090476
http://dx.doi.org/10.1016/j.omto.2022.08.004

Ejemplares similares